Novavax, Inc. (NASDAQ:NVAX) Receives Consensus Recommendation of "Hold" from Analysts

Key Points

• Consensus "Hold": Ten analysts cover Novavax with a consensus rating of "Hold" (3 sell, 2 hold, 5 buy) and an average 12‑month price target of $11.88.
• Quarterly beat but mixed outlook: Novavax reported $0.11 EPS vs. a -$0.66 estimate and revenue of $136.4M (up 66.6% YoY), yet analysts still forecast -1.46 EPS for the current year.
• Shares trade around $8.12 with a 52‑week range of $5.35–$11.97, a market cap of about $1.32B and a high beta (2.65), reflecting elevated volatility.

Shares of Novavax, Inc. (NASDAQ:NVAX - Get Free Report) have received an average rating of "Hold" from the ten ratings firms that are covering the firm, Marketbeat Ratings reports. Three analysts have rated the stock with a sell recommendation, two have assigned a hold recommendation and five have given a buy recommendation to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $11.8750.

Several research firms recently issued reports on NVAX. HC Wainwright increased their target price on Novavax from $11.00 to $16.00 and gave the stock a "buy" rating in a research note on Friday, February 27th. BTIG Research reissued a "buy" rating and set a $19.00 target price on shares of Novavax in a research note on Tuesday, January 20th. Jefferies Financial Group reissued a "buy" rating on shares of Novavax in a research note on Thursday, March 12th. B. Riley Financial reissued a "buy" rating on shares of Novavax in a research note on Thursday. Finally, Weiss Ratings raised Novavax from a "sell (d+)" rating to a "hold (c-)" rating in a research note on Thursday, March 12th.

Novavax Stock Performance

Novavax stock opened at $8.12 on Monday. Novavax has a fifty-two week low of $5.35 and a fifty-two week high of $11.97. The firm has a 50 day moving average price of $9.15 and a 200 day moving average price of $8.25. The company has a market capitalization of $1.32 billion, a PE ratio of 3.37 and a beta of 2.65.

Novavax (NASDAQ:NVAX - Get Free Report) last posted its earnings results on Thursday, February 26th. The biopharmaceutical company reported $0.11 earnings per share for the quarter, beating the consensus estimate of ($0.66) by $0.77. Novavax had a net margin of 39.19% and a negative return on equity of 673.17%. The firm had revenue of $136.40 million during the quarter, compared to the consensus estimate of $90.26 million. During the same quarter last year, the firm earned ($0.51) EPS. The firm's revenue for the quarter was up 66.6% on a year-over-year basis. As a group, equities research analysts forecast that Novavax will post -1.46 earnings per share for the current year.

Hedge Funds Weigh In On Novavax

Hedge funds have recently bought and sold shares of the company. Flagship Harbor Advisors LLC acquired a new position in Novavax during the 4th quarter worth about $33,000. Quarry LP acquired a new position in Novavax during the 3rd quarter worth about $33,000. State of Wyoming acquired a new position in Novavax during the 2nd quarter worth about $52,000. Mirae Asset Global Investments Co. Ltd. raised its position in Novavax by 25.8% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,896 shares of the biopharmaceutical company's stock valued at $53,000 after purchasing an additional 1,617 shares in the last quarter. Finally, Danske Bank A S acquired a new stake in Novavax in the 3rd quarter valued at about $64,000. Institutional investors and hedge funds own 53.04% of the company's stock.

Novavax Company Profile

Novavax, Inc is a clinical-stage biotechnology company headquartered in Gaithersburg, Maryland, that specializes in the discovery, development and commercialization of next-generation vaccines to prevent serious infectious diseases. Founded in 1987, the company has built a platform based on recombinant nanoparticle technology and its proprietary Matrix-M™ adjuvant to enhance immune responses.

The company's lead product is NVX-CoV2373, a protein-based vaccine designed to elicit a robust immune response against the SARS-CoV-2 virus.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.